Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab
PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events. The clinical benefits presumably result from favorable effects on atherosclerotic plaques. Lipid-core and plaque inflammation have been recognized as main determinants of risk for plaque rupture and cardiovascular events. Both can be noninvasively assessed with carotid MRI. We studied if PCSK9 inhibition with alirocumab induces regression in lipid-core or plaque inflammation within 6 months as measured by MRI. Patients with non-calcified carotid plaque(s) and baseline LDL-C ≥ 70 mg/dl, who were statin-intolerant or taking a low-dose statin (≤ 10 mg per day of atorvastatin or an equivalent), received subcutaneous alirocumab 150 mg every 2 weeks. Carotid MRI was performed at baseline and 6 months after treatment, including pre- and post-contrast images for measuring percent lipid-core volume (%LC) and dynamic contrast-enhanced images for measuring microvessel leakiness (Ktrans), a marker of inflammation. Twenty-eight patients completed the study (69 ± 9 years; 64% male). Alirocumab led to significant changes in LDL-C (p < 0.001) and high-density lipoprotein cholesterol (HDL-C) (p = 0.003). At 6 months, there was a significant reduction in %LC (mean: - 2.1% [- 3.5, - 0.7], p = 0.005; a 17% reduction from baseline of 9.9%) without significant changes in lumen/wall area or in the inflammatory index Ktrans. Carotid plaque lipid content was reduced by 17% after 6 months of PCSK9 inhibition with alirocumab. This was seen before observable changes in lumen or wall areas, which supports pursing plaque lipid content as a more sensitive marker of therapeutic response compared to lumen or wall areas in future technical developments and serial studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
The international journal of cardiovascular imaging - 37(2021), 4 vom: 04. Apr., Seite 1415-1422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.07.2021 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10554-020-02115-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319568717 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319568717 | ||
| 003 | DE-627 | ||
| 005 | 20231225171728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10554-020-02115-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319568717 | ||
| 035 | |a (NLM)33392875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2021 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PCSK9 inhibitors lower low-density lipoprotein cholesterol (LDL-C) and reduce cardiovascular events. The clinical benefits presumably result from favorable effects on atherosclerotic plaques. Lipid-core and plaque inflammation have been recognized as main determinants of risk for plaque rupture and cardiovascular events. Both can be noninvasively assessed with carotid MRI. We studied if PCSK9 inhibition with alirocumab induces regression in lipid-core or plaque inflammation within 6 months as measured by MRI. Patients with non-calcified carotid plaque(s) and baseline LDL-C ≥ 70 mg/dl, who were statin-intolerant or taking a low-dose statin (≤ 10 mg per day of atorvastatin or an equivalent), received subcutaneous alirocumab 150 mg every 2 weeks. Carotid MRI was performed at baseline and 6 months after treatment, including pre- and post-contrast images for measuring percent lipid-core volume (%LC) and dynamic contrast-enhanced images for measuring microvessel leakiness (Ktrans), a marker of inflammation. Twenty-eight patients completed the study (69 ± 9 years; 64% male). Alirocumab led to significant changes in LDL-C (p < 0.001) and high-density lipoprotein cholesterol (HDL-C) (p = 0.003). At 6 months, there was a significant reduction in %LC (mean: - 2.1% [- 3.5, - 0.7], p = 0.005; a 17% reduction from baseline of 9.9%) without significant changes in lumen/wall area or in the inflammatory index Ktrans. Carotid plaque lipid content was reduced by 17% after 6 months of PCSK9 inhibition with alirocumab. This was seen before observable changes in lumen or wall areas, which supports pursing plaque lipid content as a more sensitive marker of therapeutic response compared to lumen or wall areas in future technical developments and serial studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alirocumab | |
| 650 | 4 | |a Carotid plaque | |
| 650 | 4 | |a LDL | |
| 650 | 4 | |a Magnetic resonance imaging | |
| 650 | 4 | |a PCSK9 | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Anticholesteremic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a PCSK9 Inhibitors |2 NLM | |
| 650 | 7 | |a Serine Proteinase Inhibitors |2 NLM | |
| 650 | 7 | |a PCSK9 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.21.- |2 NLM | |
| 650 | 7 | |a alirocumab |2 NLM | |
| 650 | 7 | |a PP0SHH6V16 |2 NLM | |
| 700 | 1 | |a Lepor, Norman E |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, Gádor |e verfasserin |4 aut | |
| 700 | 1 | |a Contreras, Laurn |e verfasserin |4 aut | |
| 700 | 1 | |a Hippe, Daniel S |e verfasserin |4 aut | |
| 700 | 1 | |a Isquith, Daniel A |e verfasserin |4 aut | |
| 700 | 1 | |a Balu, Niranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Kedan, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Simonini, Americo A |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xue-Qiao |e verfasserin |4 aut | |
| 700 | 1 | |a Hatsukami, Thomas S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The international journal of cardiovascular imaging |d 2001 |g 37(2021), 4 vom: 04. Apr., Seite 1415-1422 |w (DE-627)NLM113949219 |x 1875-8312 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2021 |g number:4 |g day:04 |g month:04 |g pages:1415-1422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10554-020-02115-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2021 |e 4 |b 04 |c 04 |h 1415-1422 | ||